This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Isovaleramide

Shire Pharmaceuticals Group PLC

Drug Names(s): NPS 1776

Description: Isovaleramide is a neutral aliphatic amide that inhibits the liver alcohol dehydrogenases.

Deal Structure: NPS and Abbott
In February 2005, NPS received notice fromAbbott Laboratories that Abbott is terminating its license to NPS 1776. All rights to the compound, and data generated by Abbott since the license was granted in March 2000, are to become the property of NPS.

NPS and Shire
In January 2015, Shire and NPS Pharmaceuticals entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of approximately $5.2 billion. In February 2015, Shire announced the successful completion of the tender offer for all of the outstanding shares of NPS and the subsequent acquisition of NPS.


Isovaleramide News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug